437 results on '"Schmitt, Clemens"'
Search Results
2. Therapy-Induced Senescence: Opportunities to Improve Anticancer Therapy.
3. Therapy-Induced Senescence: Opportunities to Improve Anti-Cancer Therapy
4. Real world evidence reveals improved survival outcomes in biliary tract cancer through molecular matched targeted treatment
5. N6-methyladenine-mediated aberrant activation of the lncRNA SOX2OT-GLI1 loop promotes non-small-cell lung cancer stemness
6. SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma
7. The genomic and transcriptional landscape of primary central nervous system lymphoma
8. Fracture Resistance of 3D-Printed Occlusal Veneers Made from 3Y-TZP Zirconia
9. Virus-induced senescence is a driver and therapeutic target in COVID-19
10. Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors
11. Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant‐ineligible patients with newly diagnosed multiple myeloma
12. MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I
13. Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry
14. Transcriptional repression of NFKBIA triggers constitutive IKK‐ and proteasome‐independent p65/RelA activation in senescence
15. Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine—A prospective cohort study by the AGMT
16. P943: OUTCOME ANALYSIS BY CYTOGENETIC RISK GROUP AFTER RANDOMIZATION TO KRD OR KTD FOLLOWED BY K MAINTENANCE OR CONTROL IN PATIENTS WITH NTE NDMM (AGMT MM-02)
17. P429: THERAPY-INDUCED SENESCENCE TRIGGERS UPREGULATION OF ANTIGEN PRESENTATION VIA PRC2 INHIBITION AND PROMOTES ANTI-TUMOUR IMMUNITY IN ACUTE MYELOID LEUKAEMIA
18. Initiation of acute graft-versus-host disease by angiogenesis
19. Pharmacological restoration and therapeutic targeting of the B-cell phenotype in classical Hodgkin lymphoma
20. H3K9me3-mediated epigenetic regulation of senescence in mice predicts outcome of lymphoma patients
21. Senescence-associated reprogramming promotes cancer stemness
22. Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis
23. Logistics of Bone Mineralization in the Chick Embryo Studied by 3D Cryo FIB‐SEM Imaging
24. B-cell–specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice
25. Integrated Information on the Structure and Composition of the Ostrich Eggshell (Struthio camelus)
26. Abstract B045: The effect of metastasis-associated in colon cancer 1 (MACC1) on therapy-induced senescence and its impact on post-senescence-driven metastasis
27. Randomized Comparison between Krd and Ktd Induction, Followed By K Maintenance or Control in Transplant Non-Eligible Patients with NDMM: Efficacy and Qol Data (AGMT-MM02 Trial)
28. Stringent Nationwide Selection Criteria for CAR-T Cell Therapy Ensure Favourable Outcome of Patients with LBCL - First Data from the Austrian CAR-T Network
29. Cox Proportional Hazards Deep Neural Network Identifies Peripheral Blood Complete Remission (PB-CR) to be at Least Equivalent to Morphologic CR in Predicting Outcomes of Patients Treated with Azacitidine - a Prospective Cohort Study By the AGMT
30. Gradients of Orientation, Composition, and Hydration of Proteins for Efficient Light Collection by the Cornea of the Horseshoe Crab
31. Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas
32. Gradients of Orientation, Composition, and Hydration of Proteins for Efficient Light Collection by the Cornea of the Horseshoe Crab
33. Inhibition of RNA Polymerase I as a Therapeutic Strategy to Promote Cancer-Specific Activation of p53
34. Evidence for Recombinant GRP78, CALR, PDIA3 and GPI as Mediators of Genetic Instability in Human CD34+ Cells
35. Cancers / DLBCL 1L - What to expect beyond R-CHOP?
36. DLBCL 1L—What to Expect beyond R-CHOP?
37. Tumor Stroma-Derived TGF-β Limits Myc-Driven Lymphomagenesis via Suv39h1-Dependent Senescence
38. Therapy-Induced Senescence As an Anti-Cancer and Immune-Stimulatory Strategy
39. Composition of the Immune Environment at Baseline Correlates with Time to Response and Treatment Outcome in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (MM) Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Observation (AGMT_MM 02 Study)
40. Peripheral Blood Complete Remission Provides Added Value to the Classical Definition of Morphologic Complete Remission - a Prospective Cohort Study of 1441 Patients with MDS, CMML and AML Treated within the Austrian Azacitidine Registry
41. Synthetic lethal metabolic targeting of cellular senescence in cancer therapy
42. Humoral and cellular immune responses in SARS-CoV-2 mRNA-vaccinated patients with cancer
43. Additional file 1 of Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry
44. sj-docx-1-tam-10.1177_17588359211042301 – Supplemental material for Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6)
45. An Autochthonous Mouse Model of Myd88- and BCL2-Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular Vulnerabilities
46. MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I
47. Adaptive T-cell immunity controls senescence-prone MyD88-or CARD11-mutant B-cell lymphomas
48. Functional Precision Medicine Vs Genomics Vs Clinical Experience: Feasibility Results from the Multicentric, Prospective, Randomized Controlled Exalt-2 Trial
49. Non-cell-autonomous tumor suppression: oncogene-provoked apoptosis promotes tumor cell senescence via stromal crosstalk
50. Quality of Life in Newly Diagnosed Patients with Multiple Myeloma Randomized to Either Krd or Ktd Induction Therapy Followed By Carfilzomib Maintenance or Control (AGMT MM 02 trial)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.